Validity and Reliability of the Standing Up From Supine Test With Parkinson's Patients
Launched by SANKO UNIVERSITY · Feb 27, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Parkinson's disease (PD) is mainly caused by progressive degeneration of the nigrostriatal dopaminergic pathway and neurons in the substantia nigra pars compacta, which come together as lewy bodies or lewy neurites. PD is the most common neurodegenerative disease after Alzheimer's disease with a prevalence of 0.3% in the general population and 1-3% in the population over 65 years of age. As the disease progresses, motor and non-motor symptoms such as resting tremor, bradykinesia, rigidity, impaired reflexes, depression, anxiety, emotional changes, cognitive impairment, difficulty in swallow...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 40 years with a renewed diagnosis of Parkinson's disease
- • Patients who have not changed medication in the last 2 months
- • Patients who can walk with or without an assistive device
- Exclusion Criteria:
- • The presence of psychological or pathological conditions that can directly affect functional activity and cause metabolic changes
- • Pregnant or breastfeeding women
- • Alcohol and substance abusers
- • Cardiovascular or metabolic disease
About Sanko University
Sanko University is a distinguished academic institution dedicated to advancing medical research and education. With a strong emphasis on clinical trials, the university fosters innovative studies aimed at improving patient outcomes and contributing to the broader healthcare landscape. Leveraging its state-of-the-art facilities and a team of experienced researchers, Sanko University collaborates with various stakeholders to explore cutting-edge therapies and treatments. The institution is committed to ethical research practices and the highest standards of scientific rigor, ensuring that all clinical trials align with regulatory guidelines and prioritize participant safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gaziantep, , Turkey
Gaziantep, Gazi̇azntep, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported